Miyashita et al.44 have also demonstrated that high CD8+ TIL levels and CD8/FOXP3 ratios in residual tumors accurately predict better clinical outcomes in patients with TNBC with non-pCR after NAC, and that the changes in these parameters in BC tissues after NAC are significantly associated with eventual clinical outcomes in TNBCs. This evidence concerns the gene CD8A and breast cancer.